Press Release

Florham Park, NJ, April 8th, 2024

Xiromed LLC today announced the launch of Ganirelix Acetate Injection 250mcg/0.5mL Pre-Filled Syringe, generic to Organon Pharmaceutical’s Ganirelix Acetate Injection, the reference listed drug (RLD).   

Ganirelix Acetate Injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.  According to IQVIA, a leading healthcare data and analytics provider, annual sales for Ganirelix Acetate Injection were $88.2m for the 12-month period ending in January, 2024.

Xiromed CEO Rob Spina commented, “I am thrilled to announce the launch of our Ganirelix Acetate Injection product.  As a leading provider of women’s health care products globally and in the United States, we are excited to further expand our offerings into the fertility space.  The use of assisted reproductive technology has grown significantly over the past decade, yet the cost burden on patients continues to be a barrier to access.  At Xiromed, we are excited to offer a high-quality and affordable option to patients and their providers to improve access and provide additional choices in family planning.”  

Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain.  Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market.  In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products.  Learn more at http://www.xiromed.com/usa/